董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Laurence M. Corash | 男 | Director and Chief Scientific Officer | 74 | 87.13万美元 | 未持股 | 2018-04-27 |
| Gail Schulze | 女 | Director | 66 | 2.75万美元 | 未持股 | 2018-04-27 |
| Timothy B. Anderson | 男 | Director | 71 | 15.45万美元 | 未持股 | 2018-04-27 |
| Daniel N. Swisher, Jr. | 男 | Director and Chairman | 55 | 13.59万美元 | 未持股 | 2018-04-27 |
| William M. Greenman | 男 | Director,President and Chief Executive Officer | 51 | 379.47万美元 | 534.65 | 2018-04-27 |
| Frank Witney | 男 | Director | 64 | 16.89万美元 | 41.98 | 2018-04-27 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Richard Benjamin | 男 | Chief Medical Officer | 58 | 150.66万美元 | 65.22 | 2018-04-27 |
| Vivek Jayaraman | 男 | Chief Commercial Officer | 43 | 220.42万美元 | 187.03 | 2018-04-27 |
| Laurence M. Corash | 男 | Director and Chief Scientific Officer | 74 | 87.13万美元 | 未持股 | 2018-04-27 |
| William M. Greenman | 男 | Director,President and Chief Executive Officer | 51 | 379.47万美元 | 534.65 | 2018-04-27 |
| Kevin D. Green | 男 | Vice President, Finance and Chief Financial Officer | 46 | 175.04万美元 | 107.62 | 2018-04-27 |
| Chrystal N. Menard | 女 | Chief Legal Officer and General Counsel | 47 | 80.43万美元 | 未持股 | 2018-04-27 |
| Carol M. Moore | 女 | Senior Vice President, Regulatory Affairs and Quality | 68 | 84.71万美元 | 未持股 | 2018-04-27 |
董事简历
中英对照 | 中文 | 英文- Laurence M. Corash
-
Laurence M. Corash，是公司的共同创始人之一。2002年12月，他担任公司的董事。 2009年7月，他担任公司的高级副总裁、首席医疗官和首席科学官。2008年3月，他担任公司的高级副总裁和首席医疗官。1996年7月，他担任公司的医疗事务部的副总裁。 1994年7月，他担任公司医疗事务部的主管。 1991至1994年到加入我公司之前，Corash我公司的一名顾问。1985年7月，他是加州大学旧金山分校的一名实验室医学的教授。1982年至1997年，他是加州大学旧金山分校的医疗中心的血液病研究所的主管。1990年2月至1994年7月，他是血液学设备FDA咨询小组的成员。2008年至2011年，他担任健康和人类服务咨询委员会的血液安全性和可靠性的企业代表。
Laurence M. Corash,one of our co-founders, has served as a member of our Board since December 2002. Dr. Corash has been our Chief Scientific Officer since July 2015. Previously, he had been our Senior Vice President and Chief Medical and Chief Scientific Officer since July 2009. Prior to that, he had been our Senior Vice President and Chief Medical Officer since March 2008 Vice President, Medical Affairs since July 1996 and Director of Medical Affairs from July 1994. Prior to that, Dr. Corash was a consultant to us. Dr. Corash has been a Professor of Laboratory Medicine at the University of California, San Francisco since July 1985. He was the Chief of the Hematology Laboratory for the Medical Center at the University of California, San Francisco from 1982 to 1997. From February 1990 to July 1994 Dr. Corash was a member of the FDA Advisory Panel for Hematology Devices. From 2008 until 2011 Dr. Corash served as the industry representative on the Department of Health and Human Services’ Advisory Committee on Blood Safety and Availability. - Laurence M. Corash，是公司的共同创始人之一。2002年12月，他担任公司的董事。 2009年7月，他担任公司的高级副总裁、首席医疗官和首席科学官。2008年3月，他担任公司的高级副总裁和首席医疗官。1996年7月，他担任公司的医疗事务部的副总裁。 1994年7月，他担任公司医疗事务部的主管。 1991至1994年到加入我公司之前，Corash我公司的一名顾问。1985年7月，他是加州大学旧金山分校的一名实验室医学的教授。1982年至1997年，他是加州大学旧金山分校的医疗中心的血液病研究所的主管。1990年2月至1994年7月，他是血液学设备FDA咨询小组的成员。2008年至2011年，他担任健康和人类服务咨询委员会的血液安全性和可靠性的企业代表。
- Laurence M. Corash,one of our co-founders, has served as a member of our Board since December 2002. Dr. Corash has been our Chief Scientific Officer since July 2015. Previously, he had been our Senior Vice President and Chief Medical and Chief Scientific Officer since July 2009. Prior to that, he had been our Senior Vice President and Chief Medical Officer since March 2008 Vice President, Medical Affairs since July 1996 and Director of Medical Affairs from July 1994. Prior to that, Dr. Corash was a consultant to us. Dr. Corash has been a Professor of Laboratory Medicine at the University of California, San Francisco since July 1985. He was the Chief of the Hematology Laboratory for the Medical Center at the University of California, San Francisco from 1982 to 1997. From February 1990 to July 1994 Dr. Corash was a member of the FDA Advisory Panel for Hematology Devices. From 2008 until 2011 Dr. Corash served as the industry representative on the Department of Health and Human Services’ Advisory Committee on Blood Safety and Availability.
- Gail Schulze
-
Gail Schulze，2007年，担任公司董事。2008年5月至2012年6月，她担任Zosano Pharma公司的首席执行官、董事会主席。这是一家私营的生物制药公司。2006年5月至2007年3月，她担任YM Biosciences US公司的首席执行官、董事；YM Biosciences, Inc公司的总裁。YM Biosciences, Inc.是一家拥有三个晚期肿瘤项目的全球生物制药公司。她2006年加入YM Biosciences公司，此前，她是Eximias Pharmaceutical Corporation的总裁、首席执行官、董事。Eximias Pharmaceutical Corporation也是一家专注于晚期肿瘤的生物制药公司。2001年至2004年，她担任 Aventis Behring LLC的首席运营官、 副行政总裁。 Aventis Behring LLC是Aventis的 一家完全独立的生物制剂子公司。1997年至2001年，她担任该公司的高级执行副总裁和首席商务官。1995年至1997年，她担任 Allegiance Healthcare Corporation的公司的副总裁，期间她领导和创立了公司的成本管理服务部。1979年至1995年，她在Baxter Healthcare Corporation的慢性病治疗商业化和全球发展部门担任过多种职务。 期间，她担任过该公司的美国管理式医疗分部的总裁，欧洲肾内科分部的总裁。Schulze女士在多家私营公司和上市公司担任过董事。她在圣克鲁斯的加州大学以优异的成绩获得了心理生物学学士，在斯坦福商学院获得了工商管理硕士。她在威斯康辛大学学校学习神经生理学。
Gail Schulze,has served as a member of our Board since 2007. From May 2008 until June 2012 she was the Chief Executive Officer and Chairman of the Board of Directors of Zosano Pharma, a biopharmaceutical company. From May 2006 to March 2007 she was the Chief Executive Officer and a director of YM Biosciences US and President, YM Biosciences, Inc., a then global biopharmaceutical organization. Prior to joining YM Biosciences in 2006 she was President, Chief Executive Officer and director of Eximias Pharmaceutical Corporation, then a late-stage biopharmaceutical company focused on oncology. From 2001 to 2004 Ms. Schulze was Chief Operating Officer and Deputy Chief Executive Officer of Aventis Behring LLC, then a fully independent biologics subsidiary of Aventis, and from 1997 to 2001 she was Senior Executive Vice President and Chief Commercial Officer. From 1995 to 1997 she was Corporate Vice President of Allegiance Healthcare Corporation, where she led the creation and management of the Cost Management Services group of divisions. From 1979 to 1995 Ms. Schulze held multiple positions within Baxter Healthcare Corporation focused on the global development and commercialization of chronic therapies, most recently as President of the US Managed Care division and President of Renal Division Europe. Ms. Schulze has served on multiple private and public boards. She received a B.A. with highest honors in psychobiology from the University of California, Santa Cruz, studied neurophysiology at the University of Wisconsin and received her M.B.A. from the Stanford Graduate School of Business. - Gail Schulze，2007年，担任公司董事。2008年5月至2012年6月，她担任Zosano Pharma公司的首席执行官、董事会主席。这是一家私营的生物制药公司。2006年5月至2007年3月，她担任YM Biosciences US公司的首席执行官、董事；YM Biosciences, Inc公司的总裁。YM Biosciences, Inc.是一家拥有三个晚期肿瘤项目的全球生物制药公司。她2006年加入YM Biosciences公司，此前，她是Eximias Pharmaceutical Corporation的总裁、首席执行官、董事。Eximias Pharmaceutical Corporation也是一家专注于晚期肿瘤的生物制药公司。2001年至2004年，她担任 Aventis Behring LLC的首席运营官、 副行政总裁。 Aventis Behring LLC是Aventis的 一家完全独立的生物制剂子公司。1997年至2001年，她担任该公司的高级执行副总裁和首席商务官。1995年至1997年，她担任 Allegiance Healthcare Corporation的公司的副总裁，期间她领导和创立了公司的成本管理服务部。1979年至1995年，她在Baxter Healthcare Corporation的慢性病治疗商业化和全球发展部门担任过多种职务。 期间，她担任过该公司的美国管理式医疗分部的总裁，欧洲肾内科分部的总裁。Schulze女士在多家私营公司和上市公司担任过董事。她在圣克鲁斯的加州大学以优异的成绩获得了心理生物学学士，在斯坦福商学院获得了工商管理硕士。她在威斯康辛大学学校学习神经生理学。
- Gail Schulze,has served as a member of our Board since 2007. From May 2008 until June 2012 she was the Chief Executive Officer and Chairman of the Board of Directors of Zosano Pharma, a biopharmaceutical company. From May 2006 to March 2007 she was the Chief Executive Officer and a director of YM Biosciences US and President, YM Biosciences, Inc., a then global biopharmaceutical organization. Prior to joining YM Biosciences in 2006 she was President, Chief Executive Officer and director of Eximias Pharmaceutical Corporation, then a late-stage biopharmaceutical company focused on oncology. From 2001 to 2004 Ms. Schulze was Chief Operating Officer and Deputy Chief Executive Officer of Aventis Behring LLC, then a fully independent biologics subsidiary of Aventis, and from 1997 to 2001 she was Senior Executive Vice President and Chief Commercial Officer. From 1995 to 1997 she was Corporate Vice President of Allegiance Healthcare Corporation, where she led the creation and management of the Cost Management Services group of divisions. From 1979 to 1995 Ms. Schulze held multiple positions within Baxter Healthcare Corporation focused on the global development and commercialization of chronic therapies, most recently as President of the US Managed Care division and President of Renal Division Europe. Ms. Schulze has served on multiple private and public boards. She received a B.A. with highest honors in psychobiology from the University of California, Santa Cruz, studied neurophysiology at the University of Wisconsin and received her M.B.A. from the Stanford Graduate School of Business.
- Timothy B. Anderson
-
Timothy B. Anderson，2003年，担任公司董事。1999年至2002年，他担任Baxter International公司的战略和业务发展部的高级副总裁。 这是一家生物制药公司。1992年到1999年，他在该公司担任多个管理职务。1992年至1997年，他担任该公司的生物科技部总裁。1993年至1997年，他担任该公司的集团副总裁。 1997年至1999年，他是Baxter公司欧洲分部的主席。2006年至2010年，他担任Puricore Public Limited Company的董事。
Timothy B. Anderson,has served as a member of our Board since 2003. Mr. Anderson was Senior Vice President of Strategy and Business Development of Baxter International, Inc., a pharmaceutical company, from 1999 until 2002 and held various management positions at Baxter International from 1992 until 1999 including President, Biotech Group from 1992 until 1997 Group Vice President from 1993 until 1997 and Chairman, Baxter Europe from 1997 until 1999. From 2006 until 2010 Mr. Anderson served as a member of the board of directors of Puricore Public Limited Company. - Timothy B. Anderson，2003年，担任公司董事。1999年至2002年，他担任Baxter International公司的战略和业务发展部的高级副总裁。 这是一家生物制药公司。1992年到1999年，他在该公司担任多个管理职务。1992年至1997年，他担任该公司的生物科技部总裁。1993年至1997年，他担任该公司的集团副总裁。 1997年至1999年，他是Baxter公司欧洲分部的主席。2006年至2010年，他担任Puricore Public Limited Company的董事。
- Timothy B. Anderson,has served as a member of our Board since 2003. Mr. Anderson was Senior Vice President of Strategy and Business Development of Baxter International, Inc., a pharmaceutical company, from 1999 until 2002 and held various management positions at Baxter International from 1992 until 1999 including President, Biotech Group from 1992 until 1997 Group Vice President from 1993 until 1997 and Chairman, Baxter Europe from 1997 until 1999. From 2006 until 2010 Mr. Anderson served as a member of the board of directors of Puricore Public Limited Company.
- Daniel N. Swisher, Jr.
-
Daniel N. Swisher, Jr.于2018年1月被任命为Jazz Pharmaceuticals Public Limited Company总裁，并从该日期起担任Jazz Pharmaceuticals Public Limited Company首席运营官至2021年5月和2022年11月至今。2003年12月至2017年12月，他担任Sunesis Pharmaceuticals, Inc.（一家生物制药公司，专注于开发血液和实体肿瘤恶性肿瘤的新型靶向癌症治疗药物）的首席执行官兼董事会成员。2001年至2003年，他还担任Sunesis的首席商务官和首席财务官。2001年之前，他曾担任各种管理职务，包括1992年至2001年担任ALZA Corporation的销售和营销高级副总裁。他目前担任Cerus公司（一家专注于输血安全领域的生物医学产品公司）的董事会主席，以及concept Therapeutics公司（一家专注于皮质醇调节疗法以解决代谢和其他严重医疗状况的制药公司）的董事会成员。他获得了耶鲁大学的学士学位和斯坦福大学商学院的工商管理硕士学位。
Daniel N. Swisher, Jr.,was appointed Jazz Pharmaceuticals Public Limited Company President as of January 2018 and also served as Jazz Pharmaceuticals Public Limited Company Chief Operating Officer from that date until May 2021 and from November 2022 to present. From December 2003 to December 2017, he was Chief Executive Officer and a member of the board of directors of Sunesis Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel targeted cancer therapeutics in hematologic and solid tumor malignancies. He also served as Chief Business Officer and Chief Financial Officer of Sunesis from 2001 to 2003. Prior to 2001, Mr. Swisher served in various management roles, including Senior Vice President of Sales and Marketing, for ALZA Corporation from 1992 to 2001. He currently serves as Chairperson of the board of directors of Cerus Corporation, a biomedical products company focused on the field of blood transfusion safety, and as a member of the board of directors of Corcept Therapeutics Inc., a pharmaceutical company focused on cortisol-modulating therapeutics to address metabolic and other serious medical conditions. Mr. Swisher received a B.A. from Yale University and an M.B.A. from the Stanford Graduate School of Business. - Daniel N. Swisher, Jr.于2018年1月被任命为Jazz Pharmaceuticals Public Limited Company总裁，并从该日期起担任Jazz Pharmaceuticals Public Limited Company首席运营官至2021年5月和2022年11月至今。2003年12月至2017年12月，他担任Sunesis Pharmaceuticals, Inc.（一家生物制药公司，专注于开发血液和实体肿瘤恶性肿瘤的新型靶向癌症治疗药物）的首席执行官兼董事会成员。2001年至2003年，他还担任Sunesis的首席商务官和首席财务官。2001年之前，他曾担任各种管理职务，包括1992年至2001年担任ALZA Corporation的销售和营销高级副总裁。他目前担任Cerus公司（一家专注于输血安全领域的生物医学产品公司）的董事会主席，以及concept Therapeutics公司（一家专注于皮质醇调节疗法以解决代谢和其他严重医疗状况的制药公司）的董事会成员。他获得了耶鲁大学的学士学位和斯坦福大学商学院的工商管理硕士学位。
- Daniel N. Swisher, Jr.,was appointed Jazz Pharmaceuticals Public Limited Company President as of January 2018 and also served as Jazz Pharmaceuticals Public Limited Company Chief Operating Officer from that date until May 2021 and from November 2022 to present. From December 2003 to December 2017, he was Chief Executive Officer and a member of the board of directors of Sunesis Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel targeted cancer therapeutics in hematologic and solid tumor malignancies. He also served as Chief Business Officer and Chief Financial Officer of Sunesis from 2001 to 2003. Prior to 2001, Mr. Swisher served in various management roles, including Senior Vice President of Sales and Marketing, for ALZA Corporation from 1992 to 2001. He currently serves as Chairperson of the board of directors of Cerus Corporation, a biomedical products company focused on the field of blood transfusion safety, and as a member of the board of directors of Corcept Therapeutics Inc., a pharmaceutical company focused on cortisol-modulating therapeutics to address metabolic and other serious medical conditions. Mr. Swisher received a B.A. from Yale University and an M.B.A. from the Stanford Graduate School of Business.
- William M. Greenman
-
William M. Greenman，2011年4月，担任公司的总裁、首席执行官、董事。2008年8月至2011年4月，他担任公司业务发展部和市场营销部的高级副总裁。2010年4月，他被任命为公司的首席商务官。2006年至2008年8月，他担任Cerus 欧洲分部的总裁。1999年至2006年，在回到Cerus之后，在短暂的风险投资业务之后，他担任公司业务发展部的副总裁。1995年，他加入我公司并担任业务发展部主管。1991年至1995年，他在Baxter公司的生物技术分部担任过多个营销和业务发展部职务。2010年6月，他担任Aduro BioTech公司的冻水。这是一家风险私人癌症疫苗公司。 他在斯坦福大学获得了经济学和生物科学的学士学位。
William M. Greenman,has served our President and Chief Executive Officer and a member of our Board since April 2011. Mr. Greenman served as our Senior Vice President, Business Development and Marketing from August 2008 until April 2011 and was named our Chief Business Officer in April 2010. Mr. Greenman served as our President, Cerus Europe, from 2006 until August 2008. From 1999 to 2006 Mr. Greenman served as our Vice President, Business Development after returning to Cerus after a brief time in the venture capital business. Prior to joining us in 1995 as Director of Business Development, Mr. Greenman worked in various marketing and business development positions in Baxter’s Biotech Division from 1991 to 1995. Mr. Greenman has served on the board of directors of Aduro Biotech, Inc., a clinical-stage immunotherapy company, since June 2010. Mr. Greenman holds a B.A.S. in economics and biological sciences from Stanford University. - William M. Greenman，2011年4月，担任公司的总裁、首席执行官、董事。2008年8月至2011年4月，他担任公司业务发展部和市场营销部的高级副总裁。2010年4月，他被任命为公司的首席商务官。2006年至2008年8月，他担任Cerus 欧洲分部的总裁。1999年至2006年，在回到Cerus之后，在短暂的风险投资业务之后，他担任公司业务发展部的副总裁。1995年，他加入我公司并担任业务发展部主管。1991年至1995年，他在Baxter公司的生物技术分部担任过多个营销和业务发展部职务。2010年6月，他担任Aduro BioTech公司的冻水。这是一家风险私人癌症疫苗公司。 他在斯坦福大学获得了经济学和生物科学的学士学位。
- William M. Greenman,has served our President and Chief Executive Officer and a member of our Board since April 2011. Mr. Greenman served as our Senior Vice President, Business Development and Marketing from August 2008 until April 2011 and was named our Chief Business Officer in April 2010. Mr. Greenman served as our President, Cerus Europe, from 2006 until August 2008. From 1999 to 2006 Mr. Greenman served as our Vice President, Business Development after returning to Cerus after a brief time in the venture capital business. Prior to joining us in 1995 as Director of Business Development, Mr. Greenman worked in various marketing and business development positions in Baxter’s Biotech Division from 1991 to 1995. Mr. Greenman has served on the board of directors of Aduro Biotech, Inc., a clinical-stage immunotherapy company, since June 2010. Mr. Greenman holds a B.A.S. in economics and biological sciences from Stanford University.
- Frank Witney
-
Frank Witney，博士，曾担任总裁，2011年7月以来首席执行官和董事。卡梅隆博士担任总裁兼首席执行官Dionex公司从2009年4月到2011年5月。2008年12月至2009年4月，卡梅隆博士担任执行副总裁兼首席商务官。此前，从2002年7月到2008年12月，卡梅隆博士担任Panomics公司的总裁兼首席执行官。卡梅隆博士Cerus公司的董事会成员。
Frank Witney served as President and Chief Executive Officer of Affymetrix, Inc., which specialized in microarray technology and cellular analysis, from 2011 through March 2016 when it was acquired by Thermo Fisher Scientific Inc. Previoly, Dr. Witney was President and Chief Executive Officer of Dionex Corp., a market leading ion and high performance liquid chromatography company. Prior to that, Dr. Witney first joined Affymetrix as Executive Vice President and Chief Commercial Officer when it acquired Panomics, Inc., a quantitative biology company, which Dr. Witney had led as President and Chief Executive Officer. He previoly held the role of President of Revvity's Drug Discovery Tools division following Revvity's acquisition of Packard BioScience in 2001, where he served as President and Chief Operating Officer. Dr. Witney also held several positions at Bio Rad Laboratories, leading that company's efforts to enter the proteomic and bioassay technologies market. Dr. Witney was a post doctoral fellow at the National Institutes of Health and holds a PhD in molecular and cell biology and a Master of Science degree in microbiology from Indiana University, as ll as a Bachelor of Science degree in microbiology from the University of Illinois. Dr. Witney is a member of the board of directors of publicly traded Cer Corporation, currently serving as lead independent director, and Standard BioTools, Inc., as ll as several privately held companies, and until 2024, was a director of Telesis Bio, Inc. (formerly known as Codex DNA). Dr. Witney is an Operating Partner at Ampersand Capital Partners. - Frank Witney，博士，曾担任总裁，2011年7月以来首席执行官和董事。卡梅隆博士担任总裁兼首席执行官Dionex公司从2009年4月到2011年5月。2008年12月至2009年4月，卡梅隆博士担任执行副总裁兼首席商务官。此前，从2002年7月到2008年12月，卡梅隆博士担任Panomics公司的总裁兼首席执行官。卡梅隆博士Cerus公司的董事会成员。
- Frank Witney served as President and Chief Executive Officer of Affymetrix, Inc., which specialized in microarray technology and cellular analysis, from 2011 through March 2016 when it was acquired by Thermo Fisher Scientific Inc. Previoly, Dr. Witney was President and Chief Executive Officer of Dionex Corp., a market leading ion and high performance liquid chromatography company. Prior to that, Dr. Witney first joined Affymetrix as Executive Vice President and Chief Commercial Officer when it acquired Panomics, Inc., a quantitative biology company, which Dr. Witney had led as President and Chief Executive Officer. He previoly held the role of President of Revvity's Drug Discovery Tools division following Revvity's acquisition of Packard BioScience in 2001, where he served as President and Chief Operating Officer. Dr. Witney also held several positions at Bio Rad Laboratories, leading that company's efforts to enter the proteomic and bioassay technologies market. Dr. Witney was a post doctoral fellow at the National Institutes of Health and holds a PhD in molecular and cell biology and a Master of Science degree in microbiology from Indiana University, as ll as a Bachelor of Science degree in microbiology from the University of Illinois. Dr. Witney is a member of the board of directors of publicly traded Cer Corporation, currently serving as lead independent director, and Standard BioTools, Inc., as ll as several privately held companies, and until 2024, was a director of Telesis Bio, Inc. (formerly known as Codex DNA). Dr. Witney is an Operating Partner at Ampersand Capital Partners.
高管简历
中英对照 | 中文 | 英文- Richard Benjamin
Richard Benjamin，他于2015年7月担任我们的首席医疗官。他担任the American Red Cross的首席医疗官，他监督大约40%血液供应的捐赠和患者安全问题。Red Cross之前，他担任Harvard University的输血医学联合项目的成人输血服务的医学主管。他是the International Society of Blood Transfusion的北美区域董事和董事会成员以及the American Association of Blood Banks的活跃成员。他担任DHHS Secretary的美国血液安全和可用性顾问委员会的职务。他是Georgetown University的病理学兼任副教授。他是超过100名同行评议的出版物的作者。他获得英国Cambridge University的免疫学博士学位并完成了Stanford University博士后研究。
Richard Benjamin was appointed our Chief Medical Officer in July 2015. From January 2006 to June 2015 he served as Chief Medical Officer for the American Red Cross, where he oversaw donor and patient safety issues for approximately 40 of the US blood supply. Dr. Benjamin is a Board Member and Regional Director for North America for the International Society of Blood Transfusion, as well as an active member of the American Association of Blood Banks. He has also served on the DHHS Secretary’s Advisory Committee on Blood Safety and Availability in the U.S. from since December 2016 and previously served on the committee from 2006 to 2007. Dr. Benjamin is an Adjunct Full Professor of Pathology at Georgetown University and author of over 100 peer-reviewed publications. He received his Ph.D. at Cambridge University, England in Immunology and completed post-doctoral research at Stanford University.- Richard Benjamin，他于2015年7月担任我们的首席医疗官。他担任the American Red Cross的首席医疗官，他监督大约40%血液供应的捐赠和患者安全问题。Red Cross之前，他担任Harvard University的输血医学联合项目的成人输血服务的医学主管。他是the International Society of Blood Transfusion的北美区域董事和董事会成员以及the American Association of Blood Banks的活跃成员。他担任DHHS Secretary的美国血液安全和可用性顾问委员会的职务。他是Georgetown University的病理学兼任副教授。他是超过100名同行评议的出版物的作者。他获得英国Cambridge University的免疫学博士学位并完成了Stanford University博士后研究。
- Richard Benjamin was appointed our Chief Medical Officer in July 2015. From January 2006 to June 2015 he served as Chief Medical Officer for the American Red Cross, where he oversaw donor and patient safety issues for approximately 40 of the US blood supply. Dr. Benjamin is a Board Member and Regional Director for North America for the International Society of Blood Transfusion, as well as an active member of the American Association of Blood Banks. He has also served on the DHHS Secretary’s Advisory Committee on Blood Safety and Availability in the U.S. from since December 2016 and previously served on the committee from 2006 to 2007. Dr. Benjamin is an Adjunct Full Professor of Pathology at Georgetown University and author of over 100 peer-reviewed publications. He received his Ph.D. at Cambridge University, England in Immunology and completed post-doctoral research at Stanford University.
- Vivek Jayaraman
Vivek Jayaraman于2016年8月被任命为Cerus首席商务官。Jayaraman从2009年10月到2016年2月担任TrivascularTechnologies，Inc.（Trivascular）销售与市场营销Vice President，监管Trivascular的商业扩张，当时Trivascular正从一家临床前风险投资支持的初创公司成长为一家公开上市的全球医疗设备公司。Jayaraman先生在宾夕法尼亚大学沃顿商学院（Wharton School at the University of Pennsylvania）获得工商管理硕士学位，并持有密歇根大学（University of Michigan）的双学士学位。
Vivek Jayaraman was appointed as Cerus’ Chief Commercial Officer in August 2016. From October 2009 to February 2016 Mr. Jayaraman served as Vice President, Sales and Marketing of TriVascular Technologies, Inc., or TriVascular, where he oversaw TriVascular’s commercial expansion as the company grew from a preclinical, venture-backed startup into a publicly traded, global medical device company. Mr. Jayaraman received his MBA from the Wharton School at the University of Pennsylvania and holds dual bachelor’s degrees from the University of Michigan.- Vivek Jayaraman于2016年8月被任命为Cerus首席商务官。Jayaraman从2009年10月到2016年2月担任TrivascularTechnologies，Inc.（Trivascular）销售与市场营销Vice President，监管Trivascular的商业扩张，当时Trivascular正从一家临床前风险投资支持的初创公司成长为一家公开上市的全球医疗设备公司。Jayaraman先生在宾夕法尼亚大学沃顿商学院（Wharton School at the University of Pennsylvania）获得工商管理硕士学位，并持有密歇根大学（University of Michigan）的双学士学位。
- Vivek Jayaraman was appointed as Cerus’ Chief Commercial Officer in August 2016. From October 2009 to February 2016 Mr. Jayaraman served as Vice President, Sales and Marketing of TriVascular Technologies, Inc., or TriVascular, where he oversaw TriVascular’s commercial expansion as the company grew from a preclinical, venture-backed startup into a publicly traded, global medical device company. Mr. Jayaraman received his MBA from the Wharton School at the University of Pennsylvania and holds dual bachelor’s degrees from the University of Michigan.
- Laurence M. Corash
Laurence M. Corash，是公司的共同创始人之一。2002年12月，他担任公司的董事。 2009年7月，他担任公司的高级副总裁、首席医疗官和首席科学官。2008年3月，他担任公司的高级副总裁和首席医疗官。1996年7月，他担任公司的医疗事务部的副总裁。 1994年7月，他担任公司医疗事务部的主管。 1991至1994年到加入我公司之前，Corash我公司的一名顾问。1985年7月，他是加州大学旧金山分校的一名实验室医学的教授。1982年至1997年，他是加州大学旧金山分校的医疗中心的血液病研究所的主管。1990年2月至1994年7月，他是血液学设备FDA咨询小组的成员。2008年至2011年，他担任健康和人类服务咨询委员会的血液安全性和可靠性的企业代表。
Laurence M. Corash,one of our co-founders, has served as a member of our Board since December 2002. Dr. Corash has been our Chief Scientific Officer since July 2015. Previously, he had been our Senior Vice President and Chief Medical and Chief Scientific Officer since July 2009. Prior to that, he had been our Senior Vice President and Chief Medical Officer since March 2008 Vice President, Medical Affairs since July 1996 and Director of Medical Affairs from July 1994. Prior to that, Dr. Corash was a consultant to us. Dr. Corash has been a Professor of Laboratory Medicine at the University of California, San Francisco since July 1985. He was the Chief of the Hematology Laboratory for the Medical Center at the University of California, San Francisco from 1982 to 1997. From February 1990 to July 1994 Dr. Corash was a member of the FDA Advisory Panel for Hematology Devices. From 2008 until 2011 Dr. Corash served as the industry representative on the Department of Health and Human Services’ Advisory Committee on Blood Safety and Availability.- Laurence M. Corash，是公司的共同创始人之一。2002年12月，他担任公司的董事。 2009年7月，他担任公司的高级副总裁、首席医疗官和首席科学官。2008年3月，他担任公司的高级副总裁和首席医疗官。1996年7月，他担任公司的医疗事务部的副总裁。 1994年7月，他担任公司医疗事务部的主管。 1991至1994年到加入我公司之前，Corash我公司的一名顾问。1985年7月，他是加州大学旧金山分校的一名实验室医学的教授。1982年至1997年，他是加州大学旧金山分校的医疗中心的血液病研究所的主管。1990年2月至1994年7月，他是血液学设备FDA咨询小组的成员。2008年至2011年，他担任健康和人类服务咨询委员会的血液安全性和可靠性的企业代表。
- Laurence M. Corash,one of our co-founders, has served as a member of our Board since December 2002. Dr. Corash has been our Chief Scientific Officer since July 2015. Previously, he had been our Senior Vice President and Chief Medical and Chief Scientific Officer since July 2009. Prior to that, he had been our Senior Vice President and Chief Medical Officer since March 2008 Vice President, Medical Affairs since July 1996 and Director of Medical Affairs from July 1994. Prior to that, Dr. Corash was a consultant to us. Dr. Corash has been a Professor of Laboratory Medicine at the University of California, San Francisco since July 1985. He was the Chief of the Hematology Laboratory for the Medical Center at the University of California, San Francisco from 1982 to 1997. From February 1990 to July 1994 Dr. Corash was a member of the FDA Advisory Panel for Hematology Devices. From 2008 until 2011 Dr. Corash served as the industry representative on the Department of Health and Human Services’ Advisory Committee on Blood Safety and Availability.
- William M. Greenman
William M. Greenman，2011年4月，担任公司的总裁、首席执行官、董事。2008年8月至2011年4月，他担任公司业务发展部和市场营销部的高级副总裁。2010年4月，他被任命为公司的首席商务官。2006年至2008年8月，他担任Cerus 欧洲分部的总裁。1999年至2006年，在回到Cerus之后，在短暂的风险投资业务之后，他担任公司业务发展部的副总裁。1995年，他加入我公司并担任业务发展部主管。1991年至1995年，他在Baxter公司的生物技术分部担任过多个营销和业务发展部职务。2010年6月，他担任Aduro BioTech公司的冻水。这是一家风险私人癌症疫苗公司。 他在斯坦福大学获得了经济学和生物科学的学士学位。
William M. Greenman,has served our President and Chief Executive Officer and a member of our Board since April 2011. Mr. Greenman served as our Senior Vice President, Business Development and Marketing from August 2008 until April 2011 and was named our Chief Business Officer in April 2010. Mr. Greenman served as our President, Cerus Europe, from 2006 until August 2008. From 1999 to 2006 Mr. Greenman served as our Vice President, Business Development after returning to Cerus after a brief time in the venture capital business. Prior to joining us in 1995 as Director of Business Development, Mr. Greenman worked in various marketing and business development positions in Baxter’s Biotech Division from 1991 to 1995. Mr. Greenman has served on the board of directors of Aduro Biotech, Inc., a clinical-stage immunotherapy company, since June 2010. Mr. Greenman holds a B.A.S. in economics and biological sciences from Stanford University.- William M. Greenman，2011年4月，担任公司的总裁、首席执行官、董事。2008年8月至2011年4月，他担任公司业务发展部和市场营销部的高级副总裁。2010年4月，他被任命为公司的首席商务官。2006年至2008年8月，他担任Cerus 欧洲分部的总裁。1999年至2006年，在回到Cerus之后，在短暂的风险投资业务之后，他担任公司业务发展部的副总裁。1995年，他加入我公司并担任业务发展部主管。1991年至1995年，他在Baxter公司的生物技术分部担任过多个营销和业务发展部职务。2010年6月，他担任Aduro BioTech公司的冻水。这是一家风险私人癌症疫苗公司。 他在斯坦福大学获得了经济学和生物科学的学士学位。
- William M. Greenman,has served our President and Chief Executive Officer and a member of our Board since April 2011. Mr. Greenman served as our Senior Vice President, Business Development and Marketing from August 2008 until April 2011 and was named our Chief Business Officer in April 2010. Mr. Greenman served as our President, Cerus Europe, from 2006 until August 2008. From 1999 to 2006 Mr. Greenman served as our Vice President, Business Development after returning to Cerus after a brief time in the venture capital business. Prior to joining us in 1995 as Director of Business Development, Mr. Greenman worked in various marketing and business development positions in Baxter’s Biotech Division from 1991 to 1995. Mr. Greenman has served on the board of directors of Aduro Biotech, Inc., a clinical-stage immunotherapy company, since June 2010. Mr. Greenman holds a B.A.S. in economics and biological sciences from Stanford University.
- Kevin D. Green
Kevin D. Green，2013年2月，被任命为公司的财务部副总裁、首席财务官。2009年3月，他担任公司的财务部副总裁、首席会计官。 2006年1月至2009年3月，他担任公司的财务部高级主管、财务总监。2000年至2006年，他在Macromedia, Inc.担任过财务办主管、助理财务总监等多个财务管理职务。Macromedia是一家软件公司。2005年，该公司被 Adobe Systems收购。 s加入Macromedia公司之前，他在普华永道会计师事务所的保险和商业咨询部任职。 Green先生是一名注册会计师。
Kevin D. Green was appointed our Vice President, Finance and Chief Financial Officer in February 2013. Prior to that, Mr. Green served as our Vice President, Finance and Chief Accounting Officer, a role to which he was appointed in March 2009. From January 2006 to March 2009 Mr. Green was our Senior Director of Finance and Controller. From 2000 until 2006 Mr. Green held various financial management positions with Macromedia, Inc., a software company acquired by Adobe Systems in 2005 including Director of Finance and Assistant Controller. Prior to joining Macromedia, Mr. Green was a member of PricewaterhouseCoopers LLP in the Assurance and Business Advisory Services division. Mr. Green is a certified public accountant.- Kevin D. Green，2013年2月，被任命为公司的财务部副总裁、首席财务官。2009年3月，他担任公司的财务部副总裁、首席会计官。 2006年1月至2009年3月，他担任公司的财务部高级主管、财务总监。2000年至2006年，他在Macromedia, Inc.担任过财务办主管、助理财务总监等多个财务管理职务。Macromedia是一家软件公司。2005年，该公司被 Adobe Systems收购。 s加入Macromedia公司之前，他在普华永道会计师事务所的保险和商业咨询部任职。 Green先生是一名注册会计师。
- Kevin D. Green was appointed our Vice President, Finance and Chief Financial Officer in February 2013. Prior to that, Mr. Green served as our Vice President, Finance and Chief Accounting Officer, a role to which he was appointed in March 2009. From January 2006 to March 2009 Mr. Green was our Senior Director of Finance and Controller. From 2000 until 2006 Mr. Green held various financial management positions with Macromedia, Inc., a software company acquired by Adobe Systems in 2005 including Director of Finance and Assistant Controller. Prior to joining Macromedia, Mr. Green was a member of PricewaterhouseCoopers LLP in the Assurance and Business Advisory Services division. Mr. Green is a certified public accountant.
- Chrystal N. Menard
Chrystal N. Menard，2012年12月，被任命为我公司的首席法务官。2011年8月至2012年10月，她担任 Zynga Inc的高级法务顾问。2011年8月，她是Cooley LLP的合伙人，主要负责公司和证券法律业务。
Chrystal N. Menard was appointed our Chief Legal Officer and General Counsel in December 2012. From August 2011 until October 2012 Ms. Menard was Senior Corporate Counsel at Zynga Inc. Prior to August 2011 Ms. Menard was a partner of the law firm presently named Cooley LLP, practicing corporate and securities law. Ms. Menard received her BS from the University of Colorado and her JD from the University of Chicago.- Chrystal N. Menard，2012年12月，被任命为我公司的首席法务官。2011年8月至2012年10月，她担任 Zynga Inc的高级法务顾问。2011年8月，她是Cooley LLP的合伙人，主要负责公司和证券法律业务。
- Chrystal N. Menard was appointed our Chief Legal Officer and General Counsel in December 2012. From August 2011 until October 2012 Ms. Menard was Senior Corporate Counsel at Zynga Inc. Prior to August 2011 Ms. Menard was a partner of the law firm presently named Cooley LLP, practicing corporate and securities law. Ms. Menard received her BS from the University of Colorado and her JD from the University of Chicago.
- Carol M. Moore
Carol M. Moore，2013年2月，被提升为公司的法规事务部和质量与临床部门的高级副总裁。2008年4月至2013年2月，她担任公司的法规事务部、质量与临床部门的发展成果。加入Cerus之前， Moore女士在Bayer Corporation担任过多种职务， 如国际法规事务部的副总裁。她在Bayer公司的生物技术产品、卫生政策和战略规划的注册和法规遵循方面从业30多年。
Carol M. Moore was promoted to Senior Vice President, Regulatory Affairs, Quality and Clinical in February 2013. From April 2008 to February 2013 Ms. Moore was our Vice President, Regulatory Affairs, Quality and Clinical. Prior to joining Cerus, Ms. Moore served in various roles at Bayer Corporation, most recently as Vice President, Worldwide Regulatory Affairs, for over 30 years focusing on the registration and regulatory compliance of Bayer’s biological and biotech products, health policy, and strategic planning.- Carol M. Moore，2013年2月，被提升为公司的法规事务部和质量与临床部门的高级副总裁。2008年4月至2013年2月，她担任公司的法规事务部、质量与临床部门的发展成果。加入Cerus之前， Moore女士在Bayer Corporation担任过多种职务， 如国际法规事务部的副总裁。她在Bayer公司的生物技术产品、卫生政策和战略规划的注册和法规遵循方面从业30多年。
- Carol M. Moore was promoted to Senior Vice President, Regulatory Affairs, Quality and Clinical in February 2013. From April 2008 to February 2013 Ms. Moore was our Vice President, Regulatory Affairs, Quality and Clinical. Prior to joining Cerus, Ms. Moore served in various roles at Bayer Corporation, most recently as Vice President, Worldwide Regulatory Affairs, for over 30 years focusing on the registration and regulatory compliance of Bayer’s biological and biotech products, health policy, and strategic planning.